147 related articles for article (PubMed ID: 12576465)
1. In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines.
Ricotti L; Tesei A; De Paola F; Ulivi P; Frassineti GL; Milandri C; Amadori D; Zoli W
Clin Cancer Res; 2003 Feb; 9(2):900-5. PubMed ID: 12576465
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.
Zoli W; Ricotti L; Tesei A; Ulivi P; Gasperi Campani A; Fabbri F; Gunelli R; Frassineti GL; Amadori D
Clin Cancer Res; 2004 Feb; 10(4):1500-7. PubMed ID: 14977854
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
Zoli W; Ricotti L; Dal Susino M; Barzanti F; Frassineti GL; Folli S; Tesei A; Bacci F; Amadori D
Br J Cancer; 1999 Oct; 81(4):609-15. PubMed ID: 10574245
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.
Gazitt Y; Rothenberg ML; Hilsenbeck SG; Fey V; Thomas C; Montegomrey W
Int J Oncol; 1998 Oct; 13(4):839-48. PubMed ID: 9735415
[TBL] [Abstract][Full Text] [Related]
5. [Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer].
Yoshimasu T; Oura S; Hirai I; Kokawa Y; Hata K; Kawago M; Tanino H; Okamura Y; Furukawa T
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1013-6. PubMed ID: 16044964
[TBL] [Abstract][Full Text] [Related]
6. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines.
Zoli W; Ricotti L; Barzanti F; Dal Susino M; Frassineti GL; Milandri C; Casadei Giunchi D; Amadori D
Int J Cancer; 1999 Jan; 80(3):413-6. PubMed ID: 9935183
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
[TBL] [Abstract][Full Text] [Related]
8. Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling.
Oliveras-Ferraros C; Vazquez-Martin A; Colomer R; De Llorens R; Brunet J; Menendez JA
Int J Oncol; 2008 Jan; 32(1):113-20. PubMed ID: 18097549
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
10. Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Nelson SD; Dry SM; Li Y; Russell TA; Singh AS; Chmielowski B; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jun; 16(11):1063-1069. PubMed ID: 28426279
[TBL] [Abstract][Full Text] [Related]
11. In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.
Tesei A; Ricotti L; De Paola F; Amadori D; Frassineti GL; Zoli W
Clin Cancer Res; 2002 Jan; 8(1):233-9. PubMed ID: 11801564
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Konecny G; Untch M; Slamon D; Beryt M; Kahlert S; Felber M; Langer E; Lude S; Hepp H; Pegram M
Breast Cancer Res Treat; 2001 Jun; 67(3):223-33. PubMed ID: 11561768
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines.
Riccardi A; Servidei T; Tornesello A; Puggioni P; Mastrangelo S; Rumi C; Riccardi R
Eur J Cancer; 1995; 31A(4):494-9. PubMed ID: 7576952
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
Makiyama A; Qin B; Uchino K; Shibata Y; Arita S; Isobe T; Hirano G; Kusaba H; Baba E; Akashi K; Nakano S
Anticancer Drugs; 2009 Feb; 20(2):123-30. PubMed ID: 19209029
[TBL] [Abstract][Full Text] [Related]
16. [Development and characterization of a gemcitabine-resistant variant of human lung adenocarcinoma cell line A549].
Dong M; Lin C; Feng FY; Zhang XY; Fu M; Liang X; Lu HY; Zha YY; Wu M
Ai Zheng; 2004 Jun; 23(6):667-71. PubMed ID: 15191667
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines.
Voigt W; Bulankin A; Müller T; Schoeber C; Grothey A; Hoang-Vu C; Schmoll HJ
Clin Cancer Res; 2000 May; 6(5):2087-93. PubMed ID: 10815936
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma.
Sun L; Zhou DS; Zhang P; Li QH; Liu P
Int J Pharm; 2015 Jan; 478(1):308-317. PubMed ID: 25433201
[TBL] [Abstract][Full Text] [Related]
19. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
[TBL] [Abstract][Full Text] [Related]
20. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
